New IMpassion130 results support combination immunotherapy in TNBC

Atezolizumab in combination with chemotherapy could be a first line treatment option for patients with metastatic triple-negative breast cancer with high PD-L1 expression, the second interim OS analysis from the IMpassion130 trial suggests. The encouraging results seen with drugs inhibiting PD-L1 and PD-1 in non-breast tumours may also be expected with some patients with triple-negative ...